Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in Endometrial Cancer with Zoptarelin Doxorubicin at ASCO
QUÉBEC CITY, May 22, 2014 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that a poster will be presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. The poster will be presented by lead investigator, David S. Miller MD, of the University of Texas Southwestern Medical Center in Dallas, during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held May 30-June 4, 2014 in Chicago. There are currently over 100 sites in operation and over 150 patients have been recruited for this ZoptEC Phase 3 trial.
|Abstract TPS5630:||"ZoptEC: Phase 3 study of zoptarelin doxorubicin (AEZS-108) in platinum-taxane pretreated endometrial cancer (Study AEZS-108-050)", David S. Miller, Hani Gabra, Guenter Emons, D. Scott McMeekin, Amit M. Oza, Sarah Madhu Temkin, Ignace Vergote.|
|Presenter:||Dr. David S. Miller|
|Poster Session:||Gynecologic Cancer|
|Date & Time:||Saturday, May 31, 2014, 8:00 am - 11:45 am (Central time)|
|Venue:||S Hall A2, McCormick Place, Chicago|
About Zoptarelin Doxorubicin
Zoptarelin doxorubicin represents a new targeting concept in oncology using a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin. Zoptarelin doxorubicin is the first intravenous drug in advanced clinical development that directs the chemotherapy agent specifically to LHRH-receptor expressing tumors, resulting in a more targeted treatment with less damage to healthy tissue. The Company is currently conducting a Phase 3 trial in endometrial cancer under a Special Protocol Assessment, while zoptarelin doxorubicin is also in an investigator-initiated Phase 2 trial in prostate cancer. Aeterna Zentaris owns the worldwide rights to this compound.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company's pipeline encompasses compounds at various stages of development. For more information, visit www.aezsinc.com.
SOURCE Aeterna Zentaris Inc.For further information:
Director of Communications
(418) 652-8525 ext. 406